Clinical Trial Update: Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial assessing the diagnostic performance of the radiotracer [18F]PSMA-1007 PET/CT for newly diagnosed prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-PSMA-1007 (PSMA-1007 radiotracer)

Snippet

Sponsor: ABX advanced biochemical compounds GmbH | Conditions: Prostate Cancer | Phase 3 | Status: RECRUITING